Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib plus methotrexate in moderately to severely active rheumatoid arthritis with inadequate response to methotrexate
NL-OMON45740Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in rheumatoid arthritis (RA) (4 arms), sponsored by Gilead Sciences. Primary endpoint: ACR20 response at Week 12. Started Dec 2017; status: active, not recruiting.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON45740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45740.